Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free NEUP Stock Alerts

Neuphoria Therapeutics (NEUP) Competitors

Neuphoria Therapeutics logo
$3.57 +0.08 (+2.29%)
Closing price 07/14/2026 04:00 PM Eastern
Extended Trading
$3.55 -0.02 (-0.53%)
As of 07/14/2026 05:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

NEUP vs. HYFT, CING, PLRX, CYPH, and MNOV

Should you buy Neuphoria Therapeutics stock or one of its competitors? MarketBeat compares Neuphoria Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neuphoria Therapeutics include MindWalk (HYFT), Cingulate (CING), Pliant Therapeutics (PLRX), Cypherpunk Technologies (CYPH), and MediciNova (MNOV). These companies are all part of the "pharmaceutical products" industry.

How does Neuphoria Therapeutics compare to MindWalk?

MindWalk (NASDAQ:HYFT) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Neuphoria Therapeutics has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. MindWalk's return on equity of -69.37% beat Neuphoria Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MindWalk-66.79% -69.37% -39.74%
Neuphoria Therapeutics N/A -76.93%-54.76%

MindWalk presently has a consensus price target of $5.00, suggesting a potential upside of 237.84%. Neuphoria Therapeutics has a consensus price target of $21.00, suggesting a potential upside of 488.24%. Given Neuphoria Therapeutics' higher possible upside, analysts clearly believe Neuphoria Therapeutics is more favorable than MindWalk.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MindWalk
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60
Neuphoria Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

6.7% of MindWalk shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 6.8% of MindWalk shares are held by insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Neuphoria Therapeutics has lower revenue, but higher earnings than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MindWalk$17.59M3.88-$21.69M-$0.20N/A
Neuphoria Therapeutics$15.65M1.23-$370K-$11.06N/A

In the previous week, MindWalk had 3 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 5 mentions for MindWalk and 2 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 0.94 beat MindWalk's score of 0.52 indicating that Neuphoria Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MindWalk
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Neuphoria Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

MindWalk has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Summary

MindWalk beats Neuphoria Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to Cingulate?

Neuphoria Therapeutics (NASDAQ:NEUP) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Neuphoria Therapeutics has higher revenue and earnings than Cingulate. Cingulate is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuphoria Therapeutics$15.65M1.23-$370K-$11.06N/A
CingulateN/AN/A-$22.45M-$4.23N/A

Neuphoria Therapeutics presently has a consensus price target of $21.00, indicating a potential upside of 488.24%. Cingulate has a consensus price target of $27.33, indicating a potential upside of 480.33%. Given Neuphoria Therapeutics' higher probable upside, research analysts clearly believe Neuphoria Therapeutics is more favorable than Cingulate.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuphoria Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Cingulate
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by company insiders. Comparatively, 5.3% of Cingulate shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Neuphoria Therapeutics' return on equity of -76.93% beat Cingulate's return on equity.

Company Net Margins Return on Equity Return on Assets
Neuphoria TherapeuticsN/A -76.93% -54.76%
Cingulate N/A -365.15%-158.55%

Neuphoria Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Cingulate has a beta of -0.91, suggesting that its stock price is 191% less volatile than the broader market.

In the previous week, Neuphoria Therapeutics had 1 more articles in the media than Cingulate. MarketBeat recorded 2 mentions for Neuphoria Therapeutics and 1 mentions for Cingulate. Neuphoria Therapeutics' average media sentiment score of 0.94 beat Cingulate's score of 0.93 indicating that Neuphoria Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Neuphoria Therapeutics Positive
Cingulate Positive

Summary

Neuphoria Therapeutics beats Cingulate on 9 of the 14 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to Pliant Therapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

Neuphoria Therapeutics currently has a consensus price target of $21.00, indicating a potential upside of 488.24%. Pliant Therapeutics has a consensus price target of $3.00, indicating a potential upside of 175.23%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Neuphoria Therapeutics is more favorable than Pliant Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuphoria Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Pliant Therapeutics
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80

Neuphoria Therapeutics has higher revenue and earnings than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuphoria Therapeutics$15.65M1.23-$370K-$11.06N/A
Pliant Therapeutics$1.58M42.72-$149.34M-$1.84N/A

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by insiders. Comparatively, 8.7% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Pliant Therapeutics had 1 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 3 mentions for Pliant Therapeutics and 2 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 0.94 beat Pliant Therapeutics' score of 0.87 indicating that Neuphoria Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neuphoria Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pliant Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Neuphoria Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

Pliant Therapeutics' return on equity of -58.11% beat Neuphoria Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Neuphoria TherapeuticsN/A -76.93% -54.76%
Pliant Therapeutics N/A -58.11%-44.37%

Summary

Pliant Therapeutics beats Neuphoria Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to Cypherpunk Technologies?

Cypherpunk Technologies (NASDAQ:CYPH) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

Cypherpunk Technologies has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

Cypherpunk Technologies' return on equity of -48.33% beat Neuphoria Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cypherpunk TechnologiesN/A -48.33% -42.21%
Neuphoria Therapeutics N/A -76.93%-54.76%

Cypherpunk Technologies presently has a consensus price target of $0.90, suggesting a potential upside of 22.98%. Neuphoria Therapeutics has a consensus price target of $21.00, suggesting a potential upside of 488.24%. Given Neuphoria Therapeutics' higher probable upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Cypherpunk Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cypherpunk Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50
Neuphoria Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Cypherpunk Technologies has higher earnings, but lower revenue than Neuphoria Therapeutics. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cypherpunk TechnologiesN/AN/A$4.82M-$0.02N/A
Neuphoria Therapeutics$15.65M1.23-$370K-$11.06N/A

30.5% of Cypherpunk Technologies shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 3.5% of Cypherpunk Technologies shares are owned by company insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Neuphoria Therapeutics had 1 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 2 mentions for Neuphoria Therapeutics and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 1.87 beat Neuphoria Therapeutics' score of 0.94 indicating that Cypherpunk Technologies is being referred to more favorably in the media.

Company Overall Sentiment
Cypherpunk Technologies Very Positive
Neuphoria Therapeutics Positive

Summary

Cypherpunk Technologies beats Neuphoria Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Neuphoria Therapeutics compare to MediciNova?

Neuphoria Therapeutics (NASDAQ:NEUP) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by insiders. Comparatively, 14.0% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Neuphoria Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

Neuphoria Therapeutics presently has a consensus target price of $21.00, suggesting a potential upside of 488.24%. MediciNova has a consensus target price of $8.33, suggesting a potential upside of 508.27%. Given MediciNova's stronger consensus rating and higher possible upside, analysts clearly believe MediciNova is more favorable than Neuphoria Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuphoria Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
MediciNova
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.67

In the previous week, Neuphoria Therapeutics and Neuphoria Therapeutics both had 2 articles in the media. Neuphoria Therapeutics' average media sentiment score of 0.94 beat MediciNova's score of 0.44 indicating that Neuphoria Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Neuphoria Therapeutics Positive
MediciNova Neutral

Neuphoria Therapeutics has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neuphoria Therapeutics$15.65M1.23-$370K-$11.06N/A
MediciNova$410K164.47-$12M-$0.23N/A

Neuphoria Therapeutics has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Neuphoria Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Neuphoria TherapeuticsN/A -76.93% -54.76%
MediciNova -1,962.98%-27.28%-25.24%

Summary

MediciNova beats Neuphoria Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Neuphoria Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NEUP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEUP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NEUP vs. The Competition

Export
MetricNeuphoria TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$18.86M$3.68B$6.85B$12.44B
Dividend YieldN/A2.19%2.68%8.42%
P/E Ratio-0.3220.9827.0124.38
Price / Sales1.23311.11522.3492.57
Price / Cash22.39143.6648.5959.36
Price / Book0.358.5410.806.33
Net Income-$370K$23.83M$3.59B$331.02M
7 Day Performance1.42%-2.77%-1.49%-0.33%
1 Month Performance-16.78%5.85%2.79%-1.29%
1 Year Performance-52.78%52.15%28.56%21.30%

Neuphoria Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NEUP
Neuphoria Therapeutics
3.1234 of 5 stars		$3.57
+2.3%		$21.00
+488.2%		-53.6%$18.86M$15.65MN/AN/A
HYFT
MindWalk
3.1436 of 5 stars		$1.57
flat		$5.00
+218.5%		N/A$72.47M$17.59MN/A80
CING
Cingulate
3.1579 of 5 stars		$5.38
flat		$27.33
+408.1%		-0.4%$72.46MN/AN/A20
PLRX
Pliant Therapeutics
2.5438 of 5 stars		$1.17
flat		$3.00
+156.4%		-24.8%$72.45M$1.58MN/A90
CYPH
Cypherpunk Technologies
2.3343 of 5 stars		$0.67
flat		$0.90
+35.1%		+121.7%$70.91MN/AN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NEUP) was last updated on 7/15/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel